<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03272230</url>
  </required_header>
  <id_info>
    <org_study_id>C16-87</org_study_id>
    <secondary_id>2017-A00416-47</secondary_id>
    <nct_id>NCT03272230</nct_id>
  </id_info>
  <brief_title>Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System</brief_title>
  <acronym>ECOCAPTURE</acronym>
  <official_title>Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apathy can be defined as a quantitative reduction of voluntary or goal-directed behavior.

      So, the investigators propose a behavioral approach for assessing apathy, to obtain a
      quantifiable and objective signature of reduced goal-directed behavior by directly observing
      a patient in a real-life situation.

      ECOCAPTURE consists of a multi-step scenario in a functional exploration platform equipped
      with data acquisition system based on video and sensors that track a participant's behavior.

      The primary objective of this trial is to create a diagnostic tool for apathy, based on the
      video and sensors metrics.

      A secondary objective of this trial is to validate a new experimental task (ICM_APATHY_TASKS)
      to test independently three main presumed mechanisms of apathy (motivation, cognitive inertia
      and coupling between motivation and action).

      Another secondary objective aims to specify the pathophysiological mechanisms of apathy,
      corresponding to cognitive and behavioral processes, neural bases and neurohormonal
      mechanisms. The definition of pathophysiological mechanisms will allow the classification of
      apathetic patients (or several forms of apathy) and indicate which mechanism (s) best
      explains the apathy in a given patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pilot study ECOCAPTURE (ClinicalTrials.gov/NCT02496312, 2015) applied to a group of
      participants with the behavioural variant of frontotemporal lobar degeneration (bvFTLD)
      matched for age, gender and level of education to healthy participants (n=7 per group). This
      pilot validated the concept of ECOCAPTURE.

      The purpose of this trial is to continue the implementation of the ECOCAPTURE tool, extending
      it to three pathological models: bvFTLD, Parkinson's disease and depression.

      The objectives aim to assess behavior directed towards a goal and identify apathy, analyze
      data to obtain a behavioral signature of apathy and to produce more finely differentiated
      apathetic patients profiles by specifying the pathophysiological mechanisms (cognitive
      mechanisms, as well as the neural bases and the neuro-hormonal mechanisms) underlying apathy.

      The investigators use multimodal recording tools to track behavior. A multiple-camera system
      is set up with video coverage of the whole room. A sensor (Move II, Movisens, Karlsruhe,
      Germany) fixed to the subject's hip, records data such as 3D acceleration, barometric
      pressure and temperature. From these data, secondary parameters like activity class, body
      position, steps, energy expenditure and metabolic equivalents are calculated. Video data
      analysis is performed with The Observer XT software (Noldus, Wageningen, The Netherlands)
      using an ethogram to identify the frequency and duration of behaviors. For 10 min, during the
      experimental session, participants ware eye-tracking glasses (ETG 2w, SMI, Teltow, Germany)
      that record natural gaze behavior.

      Metrics built from raw data (video, sensors) are analyzed to reveal a behavioral signature of
      apathy, highlighting a quantitative reduction in goal-directed behavior.

      The study takes place on two visits (one per day). It consists of the observation phase, a
      neuropsychological assessment, experimental tasks, some of which are computerized, an MRI
      examination and finally a blood test.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of each behavior from the ethogram</measure>
    <time_frame>45 min</time_frame>
    <description>[Provided by the video recording and The Observer NOLDUS software] integer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of each behavior from the ethogram</measure>
    <time_frame>45 min</time_frame>
    <description>[Provided by the video recording and The Observer NOLDUS software] integer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of each behavior from the ethogram</measure>
    <time_frame>45 min</time_frame>
    <description>[Provided by the video recording and The Observer NOLDUS software] integer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of different behaviors</measure>
    <time_frame>45 min</time_frame>
    <description>[Provided by the video recording and The Observer NOLDUS software] integer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity classes</measure>
    <time_frame>45 min</time_frame>
    <description>[Provided by the MOVE MOVISENS sensor] lying, sitting, ...</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body positions</measure>
    <time_frame>45 min</time_frame>
    <description>[Provided by the MOVE MOVISENS sensor] lying left, ...</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Energy expenditure</measure>
    <time_frame>45 min</time_frame>
    <description>[Provided by the MOVE MOVISENS sensor] kcal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MET</measure>
    <time_frame>45 min</time_frame>
    <description>[Provided by the MOVE MOVISENS sensor] The Metabolic Equivalent of Task: MET level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steps</measure>
    <time_frame>45 min</time_frame>
    <description>[Provided by the MOVE MOVISENS sensor] Counting steps.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceleration intensity</measure>
    <time_frame>45 min</time_frame>
    <description>[Provided by the MOVE MOVISENS sensor] g.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pupil Diameter x</measure>
    <time_frame>10 min</time_frame>
    <description>[Provided by the eye-tracking glasses SMI ETG 2w] mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pupil Diameter y</measure>
    <time_frame>10 min</time_frame>
    <description>[Provided by the eye-tracking glasses SMI ETG 2w] mm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICM_APATHY_TASKS</measure>
    <time_frame>At day 1</time_frame>
    <description>ICM_APATHY_TASKS global score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMSE</measure>
    <time_frame>At day 1</time_frame>
    <description>[Mini Mental State Exam] MMSE global score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MATTIS</measure>
    <time_frame>At day 1</time_frame>
    <description>[Mattis Dementia Rating Scale ] MATTIS global score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NART</measure>
    <time_frame>At day 1</time_frame>
    <description>[National Adult Reading Test] NART IQ (global score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BREF (FAB english)</measure>
    <time_frame>At day 1</time_frame>
    <description>[Frontal Assessment Battery] BREF global score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAYLING</measure>
    <time_frame>At day 1</time_frame>
    <description>[Hayling Sentence Completion test] ] HAYLING global score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAD</measure>
    <time_frame>At day 1</time_frame>
    <description>[Hospital Anxiety and Depression Scale] ]HAD global score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gray matter volume</measure>
    <time_frame>At day 2</time_frame>
    <description>[MRI analysis- Brain segmentation] mm3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White matter volume</measure>
    <time_frame>At day 2</time_frame>
    <description>[MRI analysis- Brain segmentation] mm3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Spinal Fluid volume</measure>
    <time_frame>At day 2</time_frame>
    <description>[MRI analysis- Brain segmentation] mm3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain lesion localization</measure>
    <time_frame>At day 2</time_frame>
    <description>[MRI analysis- Brain segmentation] Talairach x,y,z coordinates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>At day 1</time_frame>
    <description>Hormonal result [Interleukin-6] pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>At day 1</time_frame>
    <description>Hormonal result [Leptin] ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>At day 1</time_frame>
    <description>Hormonal result [Blood adiponectin level)] mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>At day 1</time_frame>
    <description>Hormonal result [Fasting Insulin] mUI/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Peptide</measure>
    <time_frame>At day 1</time_frame>
    <description>Diabetic result [Fasting C-Peptide level] µg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG</measure>
    <time_frame>At day 1</time_frame>
    <description>Diabetic result [Fasting Plasma Glucose] mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>At day 1</time_frame>
    <description>Diabetic result [Glycated Hemoglobin] %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K+</measure>
    <time_frame>At day 1</time_frame>
    <description>Ionogram result [Potassium] mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid</measure>
    <time_frame>At day 1</time_frame>
    <description>Ionogram result [Uric acid] µmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>At day 1</time_frame>
    <description>Ionogram result [Creatinine] µmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Protein</measure>
    <time_frame>At day 1</time_frame>
    <description>Ionogram result [Total protein] g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>At day 1</time_frame>
    <description>Inflammatory result [C-reactive protein] mG/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>At day 1</time_frame>
    <description>Hepatic result [Aspartate aminotransferase] U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>At day 1</time_frame>
    <description>Hepatic result [Alanine aminotransferase] U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GGT</measure>
    <time_frame>At day 1</time_frame>
    <description>Hepatic result [Gamma-glutamyltransferase] U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>At day 1</time_frame>
    <description>Lipidic result [Total cholesterol] mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>At day 1</time_frame>
    <description>Lipidic result [Triglycerides] mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>At day 1</time_frame>
    <description>Lipidic result [High-density lipoprotein cholesterol] mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>At day 1</time_frame>
    <description>Lipidic result [Low-density lipoprotein cholesterol] mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycerol</measure>
    <time_frame>At day 1</time_frame>
    <description>Lipidic result [Plasma glycerol concentration] mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFAs</measure>
    <time_frame>At day 1</time_frame>
    <description>Lipidic result [Plasma free fatty acids] mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSH</measure>
    <time_frame>At day 1</time_frame>
    <description>Thyroid result [Thyroid-stimulating hormone blood test] mmol/L</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Apathy</condition>
  <condition>Frontotemporal Dementia</condition>
  <condition>Parkinson Disease</condition>
  <condition>Depressive Symptoms</condition>
  <arm_group>
    <arm_group_label>bvFTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initially especially patients diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to the Rascovsky criteria (Rascovsky et al. 2011).
ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy age, sex and education matched controls
ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992).
ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initially especially patients diagnosed with depression (Major Depressive Disorder, DSM-IV)
ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ECOCAPTURE</intervention_name>
    <description>45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system</description>
    <arm_group_label>bvFTD</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Parkinson</arm_group_label>
    <arm_group_label>Depression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive and Behavioral experimental tasks</intervention_name>
    <description>Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions</description>
    <arm_group_label>bvFTD</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Parkinson</arm_group_label>
    <arm_group_label>Depression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Neuropsychological assessment</intervention_name>
    <description>MMS / ABI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING test / STARKSTEIN / DAS</description>
    <arm_group_label>bvFTD</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Parkinson</arm_group_label>
    <arm_group_label>Depression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ICM_APATHY_TASKS</intervention_name>
    <description>Apathy experimental task</description>
    <arm_group_label>bvFTD</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Parkinson</arm_group_label>
    <arm_group_label>Depression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI</description>
    <arm_group_label>bvFTD</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Parkinson</arm_group_label>
    <arm_group_label>Depression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neurohormonal mechanisms</intervention_name>
    <description>Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage</description>
    <arm_group_label>bvFTD</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Parkinson</arm_group_label>
    <arm_group_label>Depression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All groups:

          -  Ability to give informed consent for study procedures

          -  Ability to understand study instructions and to realize the cognitive tasks

          -  Person with health insurance

        Patients:

          -  MMS&gt;20

          -  Absence of another neurological or psychiatric disease

          -  Presence of a caregiver

          -  We will recruit three groups of patients:

               -  diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to
                  the Rascovsky criteria (Rascovsky et al. 2011)

               -  diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992)

               -  diagnosed with depression (Major Depressive Disorder, DSM-IV)

        Healthy age,sex, education-matched controls:

          -  MMS&gt;27

          -  Absence of neurological or psychiatric disease

        Exclusion Criteria:

          -  Standard contraindications to MRI

          -  Inability to understand study instructions

          -  Person mentioned in the article L.1121-5 to L. 1121-8 and L. 1122-12 of the French
             Public Health Code
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard LEVY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bénédicte M BATRANCOURT, PhD</last_name>
    <phone>(33-6) 60 44 79 79</phone>
    <email>benedicte.batrancourt@upmc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Armelle Ramettilacroux, Master</last_name>
    <email>armelle.ramettilacroux@icm-institute.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICM / Pitié-Salpêtrière Hospital AP-HP / CIC</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armelle Ramettilacroux, Master</last_name>
      <email>armelle.ramettilacroux@icm-institute.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2017</study_first_submitted>
  <study_first_submitted_qc>September 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apathy</keyword>
  <keyword>Goal-directed behavior</keyword>
  <keyword>Assessment</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Sensor</keyword>
  <keyword>Ecological condition</keyword>
  <keyword>Neurological disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

